Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine

Abstract

Limited data exist concerning the long-term (≥5 year) survival rates of patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) receiving chemotherapy. We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. The study included 141 patients, and all patients were followed up from the time of diagnosis until death. The median age of the patients was 59.1±9.9 years. The male-to-female ratio was 124/17; 62.4% of the patients had stage IIIB and 37.6% had stage IV NSCLC. Squamous cell carcinoma, adenocarcinoma and undifferentiated NSCLC subtypes accounted for 69.5, 17.7 and 12.7% of the cases, respectively. The overall response rate was 32.6% and the median survival time was 12.3 months (95% CI, 10.2–14.5). The median survival times for stages IIIB and IV were 12.6±1.4 and 11.9±1.7 months, respectively. The 1-, 2-, 3- and 5-year survival rates were 33, 7.5, 4.3 and 2.8%, respectively. In conclusion, cisplatin-based new-generation cytotoxic agents for combined modality therapy offer an increased hope of long-term survival for patients with locally advanced and advanced NSCLC.

Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis

“…Despite the overall poor prognosis, a small subgroup of patients with advanced NSCLC would survive more than 5 years from the literature (21)(22)(23). Treatment with EGFR TKI is reported to be significant long-term survival factor in one study (23).…”

Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer

“…As a result, some physicians have explored more aggressive treatment approaches in the setting of oligometastatic NSCLC, including the use of local therapy to eradicate all known sites of disease (primary tumor and metastases). This so-called "curative intent" approach to oligometastatic patients has been associated with a 5-year survival of around 32% [3][4][5][6][7][8], which is far greater than survival associated with the general stage IV population treated palliatively (5-year survival, 4%) [9].…”

Protection Against Lung Cancer Patient Plasma-Induced Lymphocyte Suppression byGanoderma LucidumPolysaccharides

“…Lung cancer is a major cause of disease burden and loss of life in the US and worldwide [33,34]. It is estimated by the American Cancer Society that there will be 228,190 new cases of lung cancer and 159,480 deaths attributed to lung cancer in 2013.…”